Mitochondrial Disruption by Amyloid Beta 42 Identified by Proteomics and Pathway Mapping

Patricia Sinclair 1, Ancha Baranova 2 and Nadine Kabbani 2,*

1 Interdisciplinary Program in Neuroscience, School of Systems Biology, George Mason University, Fairfax, VA 22030, USA; psincla2@gmu.edu
2 School of Systems Biology, George Mason University, Manassas VA 20110, USA; abaranov@gmu.edu
* Correspondence: nkkabbani@gmu.edu

Abstract: Alzheimer’s disease (AD) is marked by chronic neurodegeneration associated with the occurrence of plaques containing amyloid β (Aβ) proteins in various parts of the human brain. An increase in several Aβ fragments is well documented in patients with AD and anti-amyloid targeting is an emerging area of therapy. Soluble Aβ can bind to various cell surface and intracellular molecules with the pathogenic Aβ42 fragment leading to neurotoxicity. Here we examined the effect of Aβ42 on network adaptations in the proteome of nerve growth factor (NGF) differentiated PC12 cells using liquid-chromatography electrospray ionization mass spectrometry (LC-ESI MS/MS) proteomics. Whole-cell peptide mass fingerprinting was coupled to bioinformatic gene set enrichment analysis (GSEA) in order to identify differentially represented proteins and related gene ontology (GO) pathways within Aβ42 treated cells. Our results underscore a role for Aβ42 in disrupting proteome responses for signaling, bioenergetics, and morphology in mitochondria. These findings highlight the specific components of the mitochondrial response during Aβ42 neurotoxicity and suggest several new biomarkers for detection and surveillance of amyloid disease.

Keywords: Alzheimer’s; amyloid; bioenergetics; mitochondria; prohibitin; proteomics

1. Introduction

Alzheimer’s disease (AD) is the most common cause of human dementia and a major public health problem. Commonly prescribed drugs for treatment include acetylcholinesterase (AChE) inhibitors, which lessen cognitive symptoms without halting neurodegeneration [1]. A recently approved monoclonal antibody, aducanumab (Aduhelm), which specifically targets Aβ oligomers, appears to slow disease progression [2]. In clinical studies, however, aducanumab was also associated with transient swelling of the brain and hemorrhaging, thus increasing the urgency for a better understanding of the cellular effects of Aβ.

Amyloid plaques and neurofibrillary tangles (NFT) of aggregated hyperphosphorylated tau are the primary histopathological lesions of AD [3]. Amyloid plaques consist of highly structured Aβ peptides generated by β- and γ-secretase cleavage of APP in cells [4]. High levels of Aβ42 were shown to contribute to neural damage in early and late stages of AD [5]. Soluble, low molecular weight, Aβ42 oligomers contribute to cell damage and neurotoxicity [6], with the pathogenicity of amyloid proteins developing well before the emergence of measurable cognitive symptoms. In fact, memory deficits in mice correlate with the early stages of Aβ42 oligomer formation during Aβ deposition [7].

A mechanistic understanding of Aβ42 mediated neurotoxicity was obtained in cultured neural cells exposed to various concentrations of the amyloid protein [8]. Several subcellular and molecular targets of Aβ42 toxicity were identified [9,10]. In hippocampal neurons, Aβ42 peptides tend to aggregate within lipid rafts and drive Ca2+-mediated neurotoxicity (Abramov et al., 2004). Aβ42 oligomers also induce mitochondrial dysfunction and oxidative stress in neurons through calcium mediated neurotoxicity [11]. In addition,
various cell surface receptors can bind to Aβ42, including metabotropic glutamate receptors (mGluR5), nicotinic acetylcholine receptor (α7nAChR), N-methyl-D-aspartic acid receptor (NMDAR), β-adrenergic receptor (β-AR), erythropoietin-producing hepatoma cell line receptor (EphR), and paired immunoglobulin-like receptor B (PirB) [12,13].

In this study, we examined whole cell proteomic adaptations to Aβ42 (Aβ42 proteome) in PC12 cells, which are an established model system for amyloid cytotoxicity [14]. Our findings underscore the role of mitochondrial responses to Aβ42 and delineate specific pathways for ion transport, calcium signaling, and energy production that may contribute to the early stages of AD.

2. Materials and Methods

2.1. Cell Culture and Treatment

Pheochromocytoma (PC12) adherent cells (ATCC® CRL-1721.1™) were proliferated in RPMI-1640 (ATCC), which was supplemented with 10% horse serum (HS), 5% fetal bovine serum (FBS), and 1% pen/strep on collagen (50 µg/mL) at 37 °C and 5% CO2. Cells were differentiated using nerve growth factor (NGF, 200 ng/mL, Millipore, Burlington, MA, USA) in RPMI-1640, 2% HS, 1% FBS, and 0.2% pen/strep for 24 h before treating with 100 nM Aβ42. Soluble oligomeric Aβ42 peptides were prepared as described in Arora et al. [15]. These preparations were shown to yield a stable oligomeric form of Aβ42. Daily media and treatment changes ensured consistent exposure to Aβ42 [16]. After three days, cells were solubilized by the addition of a 0.1% Triton X-100 lysis buffer (Triton X-100, 1 M Tris HCl, 1.5 M NaCl, 0.25 M EDTA, and 10% glycerol, in the presence of protease inhibitors (Complete Mini, Roche, Basel, Switzerland)) in 10 mL of lysis buffer as described [17]. The protein concentration was determined by a Bradford assay.

2.2. Liquid-Chromatography Electrospray Ionization Mass Spectrometry

Sample preparation for proteomics was conducted as described in [18]. Briefly, 100 µg of protein was precipitated by the addition of acetone 100 µL at 4 °C for 5 min and then centrifuged for 3 min at 16,000× g. The pellet was sequentially treated with 8 M urea, 1 M dithiothreitol, 0.5 M iodoacetamide, and 2 µL (0.5 µg/µL) trypsin in 0.5 M ammonium bicarbonate, then incubated at 37 °C for 5 h to denature, reduce, alkylate, and digest proteins. The sample was desalted using C-18 ZipTips (Millipore), dehydrated in a SpeedVac for 18 min, and reconstituted in 0.1% formic acid for a final volume of 20 µL for liquid-chromatography electrospray ionization mass spectrometry (LC-ESI MS/MS). LC-ESI MS/MS was performed using an Exploris Orbitrap 480 equipped with an EASY-nLC 1200HPLC system (Thermo Fischer Scientific, Waltham, MA, USA). Peptides were separated using a reversed-phase PepMap RSLC 75 µm i.d by 15 cm long with a 2 µm particle size C18 LC column (Thermo Fisher Scientific, Waltham, MA, USA), eluted with 0.1% formic acid and 80% acetonitrile at a flow rate of 300 nL/min. After one full scan (60,000 resolution) from 300 m/z to 1200 m/z, high abundance peptides were selected in a data-dependent fashion for fragmentation by high-energy collision dissociation (HCD) with a normalized collision energy of 28%. Enabled filters included EASY-IC internal mass calibration, monoisotopic precursor selection, and dynamic exclusion (20 s). Peptide precursor ions with charge states from +2 to +4 were included. All samples were run in triplicate.

2.3. Protein Identification and Quantification

Proteome Discoverer v2.4 (Thermo Fisher Scientific, Waltham, MA, USA) was used to identify proteins using the SEQUEST HT search engine to compare MS spectra to the Rattus norvegicus Rat_NCBI2016 database under the following parameters: mass tolerance for precursor ions = 5 ppm; mass tolerance for fragment ions = 0.05 Da; and cut-off value for the false discovery rate (FDR) in reporting peptide spectrum matches (PSM) to the database = 1%. The abundance ratios and p-values were calculated by precursor ion
quantification in Proteome Discoverer v2.4. Non-treated NGF differentiated PC12 cells were used as a control.

2.4. Gene Set Enrichment Analysis (GSEA) and Genomic Enrichment Analysis (GEA)

Bioinformatic analysis was performed on filtered dataset proteins obtained from Proteome Discoverer v2.4 with a quantifiable spectra signal profile in at least two out of the three replicates. Proteins differentially impacted by the treatment condition were identified based on the calculated protein abundance ratio (fold-change) \( p < 0.05 \) using Proteome Discoverer. Proteins were identified by Entrez ID gene identifiers in NCBI.

For GSEA or GEA, protein identifiers, abundance ratios, and individual \( p \)-values were uploaded into Pathway Studio (PS) (www.pathwaystudio.com, accessed 2 March 2021 through 20 June 2021). GSEA was performed against the Gene Ontology (GO) pathways stored in the PS environment.

2.5. Statistics

One-way analysis of variance (ANOVA), followed by Benjamini-Hochberg post-hoc, was used to calculate \( p \)-values within Proteome Discoverer v2.4. Statistical significance of GO pathways and GEA, analyzed in Pathway Studio, was obtained using a Mann-Whitney U test. \( p \)-values of < 0.05 were considered significant. The data was organized and presented using the R package, ggplot2 [19], and Excel.

3. Results

3.1. Whole-Cell Proteome Analysis of PC12 Cells Exposed to \( \text{A}\beta_{42} \)

To uncover molecular mechanisms of \( \text{A}\beta_{42} \) mediated neurotoxicity, NGF differentiated PC12 cells were treated with 100 nM \( \text{A}\beta_{42} \) prepared and presented in a manner consistent with the formation of pathogenic oligomeric amyloid peptides [20]. PC12 cells were exposed to three days of \( \text{A}\beta_{42} \), then analyzed using LC-ESI-MS/MS. In these experiments, NGF differentiated cells not exposed to \( \text{A}\beta_{42} \) were used as the control condition. Using MS proteomic spectra identification and label-free precursor ion quantification for relative abundance [21] in Proteome Discoverer v2.4, we identified proteins significantly impacted by the presence of \( \text{A}\beta_{42} \). Pathway Studio (PS) and Gene Ontology (GO) informatic analysis was used to deduce significant molecular pathways and cellular components of the \( \text{A}\beta_{42} \) response (Figure 1).

![Figure 1. A flowchart summary of the mass spectrometry and bioinformatic analysis approach.](image-url)
MS proteomic analysis identified a total of 4206 known proteins within our cells; a complete list has been deposited in FigShare dataset (10.6084/m9.figshare.15157257). Of those, a subset of 316 proteins was identified as significantly altered by Aβ42 relative to controls (p < 0.05) and are assigned the label “Aβ42 proteome” in the study. As shown in Figure 2A (Supplementary Tables S1 and S2), within the Aβ42 proteome 226 proteins (72%) were decreased, while 90 proteins (28%) were increased. GO analysis of the Aβ42 proteome revealed an impact on mitochondrial processes (Figure 2B–D) consistent with earlier findings in neurons [22].

![Figure 2](image)

**Figure 2.** The Aβ42 proteome and GO impacted process. (A) each point on the plot represents 1 of 4206 identified proteins. The dotted line indicates the threshold of statistical significance (−log10 p-value). Green: 226 decreased proteins; red: 90 increased proteins. (B–D) the total number of significantly impacted proteins per GO domain: cellular component (B); biological process (C); and molecular function (D).

### 3.2. The Aβ42 Proteome Revolves around Mitochondria Function

Using GO analysis, 199 proteins (63%) within the Aβ42 proteome were classified as membrane-associated molecules (Figure 3A, Supplementary Tables S3 and S4). Further subcellular analysis localized these membrane proteins to mitochondria (28%), nucleus (10%), endoplasmic reticulum (10%), Golgi apparatus (1%), endosomes (3%), cell surface (2%), and/or more than one compartment (multi-compartment) (23%) (Figure 3B). Interestingly, the majority of multi-compartment proteins (76%) within the Aβ42 proteome, showed mitochondrial and nuclear placement (Figure 3C). For example, prohibitin 2 (PHB2), which was significantly downregulated by Aβ42, is known to shuttle between the mitochondria and nucleus and regulate transcription [23].
Figure 3. Subcellular distribution of membrane-associated components of the Aβ42 proteome. (A) the distribution of all 199 membrane associated proteins. (B) GO based subcellular allocation of these proteins shows: 28% mitochondria; 10% nucleus; 10% ER; 29% other organelle (e.g., proteasomes); 23% multi-compartment. (C) multi-compartment proteins show high mitochondrial and/or nuclear association.

3.3. Gene Set Enrichment Analysis of Amyloid-Associated Pathways

Using Gene Set Enrichment Analysis (GSEA) in Pathway Studio (https://www.pathwaystudio.com, accessed in 2 March 2021) [24], Aβ42 proteome functions were extracted and analyzed. A bioinformatic assessment of all significantly altered proteins within the Aβ42 proteome (Supplementary Table S5), identified 30 specific enriched GO pathways for the Aβ42 proteome (Figure 4 and Table 1). A trend for engaging adenine nucleotide transmembrane transport (ADP/ATP) and mitochondrial ribosomal proteins (mitoribosome) in the presence of amyloids emerged. This bioinformatic analysis complements previous findings, which showed an impact of amyloid on mitochondrial protein expression [25] and suggests a specific role for proteins, such as SLC25A5, in oxidative phosphorylation (OXPHOS) amyloid toxicity.

Earlier studies demonstrated an ability of Aβ [26] and α-synuclein [27], to impact mitochondrial trafficking and function. Consistently, we detected significant changes in the expression of many mitochondrial proteins (95 down-regulated; and 13 up-regulated) within the Aβ42 proteome dataset (Figure 5A, Supplementary Tables S6 and S7). GO analysis showed that these proteins were important for mitochondrial membrane organization, inner structural scaffolding, and mitoribosome function (Figure 5B). In particular, a significantly downregulated set of solute carriers (SLC) proteins, including SLC25A4 and SLC25A5, are known to mediate nucleotide (ADP/ATP) transport across the mitochondrial membrane [28]. These proteins are also known to regulate nuclear function (Figure 5C, Supplementary Tables S8 and S9) [29].
Figure 4. GSEA of the Aβ42 proteome highlights the contribution of mitochondrial pathways. A heatmap of GSEA within primary GO domains shows 30 enriched pathways within the Aβ42 proteome. The extent of protein abundance shift within Aβ42 treated cells (vs. control) is indicated.

3.4. An Analysis of Aβ42 Proteome Associated Genes and Possible Relevance to Human Disease

Genomic enrichment analysis (GEA) of the human genome was performed on the Aβ42 proteome dataset using PS. Genes that encode components of the Aβ42 proteome were found randomly distributed throughout the human genome. Interestingly, ~70% of the Aβ42 proteome appeared to localize to gene regions of disease, including rare copy number variation (e.g., microdeletions and/or duplications). A complete list of the GEA results is presented in Supplementary Table S10 and lists all genes, chromosomal location, and human disease phenotype associated with the Aβ42 proteome dataset. Figure 6, summarizes GEA of genes associated with mitochondrial proteins within the Aβ42 proteome. As shown, our results suggest a link between amyloid-associated cellular responses and various genetic factors that contribute to human disease. For example, chromosome 1p36 deletion syndrome appears impacted by amyloid-sensitive proteins encoded by the SDHB and UQCRHL gene, which both reside within that gene region and can critically contribute to cell energetics. In fact, 1p36 deletion syndrome was shown to associate with congenital cardiac abnormalities and/or developmental and intellectual deficits [30]. Another genomic region of interest resides on chromosome 17q21, housing both the BRCA1 and PHB genes, whose products are estrogen receptor (ER) sensitive [31,32]. In this case, PHB encodes the mitochondrial protein prohibitin that is significantly decreased within our dataset, suggesting a link between estrogen and amyloid responses in cells.
Table 1. GSEA identified GO pathways enriched with the Aβ₄₂ proteome data set.

| GO ID #     | Pathway Name                                           | \( p \)-Value     | # Entities Overlap |
|-------------|--------------------------------------------------------|-------------------|--------------------|
| **BIOLOGICAL PROCESS** |                                                          |                   |                    |
| GO:0051503  | adenine nucleotide transport                           | \( 2.41 \times 10^{-2} \) | 8                  |
| GO:0015868  | purine ribonucleotide transport                         | \( 2.41 \times 10^{-2} \) | 8                  |
| GO:0015865  | purine nucleotide transport                             | \( 2.41 \times 10^{-2} \) | 8                  |
| GO:0006862  | nucleotide transport                                    | \( 2.41 \times 10^{-2} \) | 8                  |
| GO:1902475  | L-alpha-amino acid transmembrane transport              | \( 1.97 \times 10^{-2} \) | 5                  |
| GO:1903825  | organic acid transmembrane transport                    | \( 4.85 \times 10^{-2} \) | 11                 |
| GO:1905039  | carboxylic acid transmembrane transport                 | \( 4.85 \times 10^{-2} \) | 11                 |
| GO:0015748  | organophosphate ester transport                         | \( 3.71 \times 10^{-2} \) | 12                 |
| GO:0001889  | liver development                                       | \( 4.33 \times 10^{-2} \) | 6                  |
| GO:1901565  | organonitrogen compound catabolic process               | \( 4.10 \times 10^{-2} \) | 18                 |
| GO:0032774  | RNA biosynthetic process                                | \( 3.83 \times 10^{-2} \) | 10                 |
| GO:2000113  | negative regulation of cellular macromolecule biosynthetic process | \( 4.64 \times 10^{-2} \) | 19                 |
| GO:0045892  | negative regulation of transcription, DNA-templated     | \( 3.94 \times 10^{-2} \) | 15                 |
| GO:0051252  | regulation of RNA metabolic process                     | \( 3.47 \times 10^{-2} \) | 44                 |
| **CELLULAR COMPONENT** |                                                          |                   |                    |
| GO:005762   | mitochondrial large ribosomal subunit                   | \( 4.86 \times 10^{-2} \) | 5                  |
| GO:000315   | organellar large ribosomal subunit                      | \( 4.86 \times 10^{-2} \) | 5                  |
| GO:005840   | ribosome                                               | \( 2.88 \times 10^{-2} \) | 8                  |
| GO:0098687  | chromosomal region                                      | \( 1.52 \times 10^{-2} \) | 6                  |
| GO:1990904  | ribonucleoprotein complex                               | \( 2.32 \times 10^{-2} \) | 14                 |
| GO:0000785  | chromatin                                              | \( 6.42 \times 10^{-3} \) | 8                  |
| **MOLECULAR FUNCTION** |                                                          |                   |                    |
| GO:0000295  | adenine nucleotide transmembrane transporter activity    | \( 2.41 \times 10^{-2} \) | 8                  |
| GO:0015216  | purine nucleotide transmembrane transporter activity     | \( 2.41 \times 10^{-2} \) | 8                  |
| GO:0015215  | nucleotide transmembrane transporter activity            | \( 2.41 \times 10^{-2} \) | 8                  |
| GO:0005346  | purine ribonucleotide transmembrane transporter activity | \( 2.65 \times 10^{-2} \) | 7                  |
| GO:0015605  | organophosphate ester transmembrane transporter activity | \( 2.41 \times 10^{-2} \) | 8                  |
| GO:0015932  | nucleobase-containing compound transmembrane transporter activity | \( 2.41 \times 10^{-2} \) | 8                  |
| GO:1901505  | carbohydrate derivative transmembrane transporter activity | \( 2.65 \times 10^{-2} \) | 7                  |
| GO:0008514  | organic anion transmembrane transporter activity         | \( 4.34 \times 10^{-2} \) | 13                 |
| GO:0008134  | transcription factor binding                            | \( 3.53 \times 10^{-2} \) | 8                  |
| GO:0016772  | transferase activity, transferring phosphorus-containing groups | \( 1.40 \times 10^{-2} \) | 9                  |
3.5. Proteomic Mechanisms of Aβ42 Cellular Calcium Signaling

Amyloid proteins were shown to increase intracellular calcium levels, leading to calcium-mediated neurotoxicity [22,33]. Aβ42 mediates cellular calcium entry through binding to cell surface receptors, such as the α7 nACh [12,13]. Therefore, the subcellular distribution of calcium binding molecules (i.e., proteins with a known calcium binding domain) and more broadly, calcium associated molecules (i.e., those with known regulation by calcium) was analyzed within the Aβ42 proteome. As shown in Figure 7, Aβ42 treatment was associated with a noticeable impact on cellular calcium signaling through the regulation of both calcium binding and associated proteins. GO domain mapping indicated that impacted proteins localize to various subcellular compartments and can traffic between important organelles. For example, FKBP1A, which was significantly up-regulated (fold-change = 4.632, p = 2.37 × 10^{-16}) in the presence of Aβ42, is a calcium binding cis-trans isomerase that modulates ryanodine receptor (RyR) activity and protein folding in the ER. Here, FKBP1A appears to participate in RyR mediated calcium flux from the ER to the mitochondria at the mitochondrial associated membrane (MAM) [34,35] (Figure 7 and Supplementary Tables S11 and S12). Overall, our proteomic findings support existing evidence on the direct ability of amyloid peptides to disrupt intracellular calcium activity in neural cells [36], and suggest a multi-compartment model for the impact of amyloids on calcium homeostasis.
Figure 6. Genomic analysis of mitochondrial protein impacted by Aβ42. Genome enrichment analysis (GEA) was used to examine the number and location of genes that encode mitochondrial components of the Aβ42 proteome. The red line indicates the total number of impacted genes/chromosome. Boxed are chromosomal regions of copy number variation that correlate with human disease. Chromosome 1, which contains 18 impacted genes, has been adjusted for size.

Figure 7. Cellular mechanisms of Aβ42 mediated calcium signaling. The subcellular distribution of calcium binding (black) and calcium associated (orange) proteins impacted by Aβ42.
4. Discussion

Neurodegeneration in the course of AD is suspected to stem from alterations in amyloid precursor protein (APP) processing, resulting in the elevation of a pathogenic Aβ42 peptide in the brain and cerebrospinal fluid (CSF) [37]. We investigated the direct impact of this pathogenic amyloid peptide on cells using whole cell proteome analysis and GO analysis. We found that Aβ42 exposure preferentially impacted proteins associated with the mitochondria including its known interactions with other cellular organelles. We also identified other pathways of known importance for amyloid protein processing including two subunits of the biogenesis of lysosome-related organelle complex 1 (BLOC1S2 and BLOC1S6) that are involved in endosome recycling, another mechanism implicated in AD [38–40]. These proteins are consistent with the concurrent activity of lysosome and autophagy pathways that known to be activated during by amyloid protein degradation in neural cells [38].

The Aβ42 proteome reveals a mechanistic framework for understanding how amyloid peptides disrupt cell bioenergetics, calcium homeostasis, and the shape and localization of mitochondrion [41]. As depicted in Figure 8, our data proposes an important impact on mitochondrial cristae scaffolding proteins and disruption to energy management through proteins such as prohibitin. Specifically, the energy producing cellular machinery, including components of metabolite transport, tricarboxylic acid cycle (TCA), the electron transport chain (ETC) (complexes I–IV), and the ATP synthase, all appear to be impacted by Aβ42. The ETC, responsible for creating and maintaining the vital H+ gradient across the mitochondrial membrane, upon exposure to Aβ42 is likely perturbed at the H+ generating complex (I, III and IV) as based on proteomic evidence of changes to components of complex II during Aβ42 exposure. Here, a down-regulation in succinate dehydrogenase (SDBH) is also predicted to disrupt the TCA cycle and its link to the ETC [42]. This proposed failure of the ETC should yield a drop in mitochondrial ATP synthesis and drive ROS production, leading to disruption in membrane potential (∆ψm) [43]. This model is consistent with the observed features of amyloid toxicity [41].

**Figure 8.** A model of mitochondrial disruption by Aβ42 based on our proteomic findings of specifically altered mitochondrial proteins (bold). 1: bioenergetics (TCA and ETC); 2: pyruvate dehydrogenase complex; 3: ATP/ADP exchange; 4: inorganic phosphate carrier; 5: glutamate/aspartate carrier; 6: LETM1 calcium transport; 7: FKBP1a stems calcium influx from ER; 8: anti-apoptotic HAX1 factor localized to the inter-membrane space through interaction with PHB2. 9: OPA-prohibitin complex stabilizes cristae; and 10: nucleoid stabilized to the IMM by PHB.
The Aβ42 proteome is also deficient in a number of other mitochondrial proteins essential for cell survival and synaptic function. For example, Aβ42 was found to decrease the expression of the pyruvate carrier MPC2, a component of the pyruvate dehydrogenase complex that transports pyruvate into the mitochondrial matrix [44]. In addition, Aβ42 was found to negatively impact the levels of proteins vital for the exchange of ATP/ADP, phosphate, and various metabolites across the mitochondrial membrane. Observed changes in several key SLC25 family transport proteins, including SLC25A4 and SLC25A5, necessary for the exchange of ATP/ADP [45], and SLC25A3, involved in phosphate transport during ATP production, suggest several mitochondrial biomarker proteins in early AD detection.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cells10092380/s1, Supplementary Tables: Table S1: All proteins significantly decreased by Aβ42 treatment, Table S2: All proteins significantly increased by Aβ42 treatment, Table S3: Membrane proteins significantly decreased by Aβ42 treatment, Table S4: Membrane proteins significantly increased by Aβ42 treatment, Table S5: Aβ42 proteomic results uploaded to Pathway Studio for GSEA, Table S6: Mitochondrial proteins significantly decreased by Aβ42 treatment, Table S7: Mitochondrial proteins significantly increased by Aβ42 treatment, Table S8: Nuclear proteins significantly decreased by Aβ42 treatment, Table S9: Nuclear proteins significantly increased by Aβ42 treatment, Table S10: Genomic Enrichment Analysis Results, Table S11: ER proteins significantly decreased by Aβ42 treatment, Table S12: ER proteins significantly decreased by Aβ42 treatment. The full dataset is available at 10.6084/m9.figshare.15157257.

Author Contributions: Conceptualization, P.S., A.B. and N.K.; methodology, P.S., A.B. and N.K.; software, P.S., A.B. and N.K.; validation, P.S., A.B. and N.K.; formal analysis, P.S.; investigation, P.S., A.B. and N.K.; resources, P.S., A.B. and N.K.; data curation, P.S.; writing—original draft preparation, P.S. and N.K.; writing—review and editing, P.S., A.B. and N.K. visualization, P.S.; supervision, N.K.; project administration, N.K.; funding acquisition, N.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data can be found in Figshare at 10.6084/m9.figshare.15157257.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Davis, J.; Couch, R. Strategizing the Development of Alzheimer’s Therapeutics. Adv. Alzheimer’s Dis. 2014, 3, 107–127. [CrossRef]
2. Tolar, M.; Abushakra, S.; Hey, J.A.; Porsteinsson, A.; Sabbagh, M. Aducanumab, Gantenerumab, BAN2401, and ALZ-801—the First Wave of Amyloid-Targeting Drugs for Alzheimer’s Disease with Potential for near Term Approval. Alzheimer’s Res. Ther. 2020, 12, 95. [CrossRef]
3. Perl, D.P. Neuropathology of Alzheimer’s Disease. J. Transl. Pers. Med. 2010, 77, 32–42. [CrossRef]
4. Chow, V.W.; Mattson, M.P.; Wong, P.C.; Gleichmann, M. An Overview of APP Processing Enzymes and Products. Neuromol. Med. 2010, 12, 1–12. [CrossRef]
5. Guimas Almeida, C.; Sadat Mirfakhar, F.; Perdigão, C.; Burrinha, T. Impact of Late-Onset Alzheimer’s Genetic Risk Factors on Beta-Amyloid Endocytic Production. Cell. Mol. Life Sci. 2018, 75, 2577–2589. [CrossRef] [PubMed]
6. Ma, Q.-L.; Yang, F.; Rosario, E.R.; Ubeda, O.J.; Beech, W.; Gant, D.J.; Chen, P.P.; Hudspeth, B.; Chen, C.; Zhao, Y.; et al. β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin. J. Neurosci. 2009, 29, 9078–9089. [CrossRef] [PubMed]
7. Koistinaho, M.; Ort, M.; Cimadevilla, J.M.; Vondrouš, R.; Cordell, B.; Koistinaho, J.; Bures, J.; Higgins, L.S. Specific Spatial Learning Deficits Become Severe with Age in β-Amyloid Precursor Protein Transgenic Mice That Harbor Diffuse β-Amyloid Deposits but Do Not Form Plaques. Proc. Natl. Acad. Sci. USA 2001, 98, 14675–14680. [CrossRef] [PubMed]
8. Fontana, I.C.; Zimmer, A.R.; Rocha, A.S.; Gossman, G.; Souza, D.O.; Lourenco, M.V.; Ferreira, S.T.; Zimmer, E.R. Amyloid-β Oligomers in Cellular Models of Alzheimer’s Disease. J. Neurochem. 2020, 155, 348–369. [CrossRef]
9. Stewart, K.L.; Radford, S.E. Amyloid Plaques beyond Aβ: A Survey of the Diverse Modulators of Amyloid Aggregation. Biophys. Rev. 2017, 9, 405–419. [CrossRef] [PubMed]
10. Chen, X.-Q.; Moberly, W.C. Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species. Front. Neurosci. 2019, 13, 659. [CrossRef]
11. Chen, G.; Xu, T.; Yan, Y.; Zhou, Y.; Jiang, Y.; Melcher, K.; Xu, H.E. Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development. *Acta Pharmacol. Sin.* 2017, 38, 1205–1235. [CrossRef]

12. Xia, M.; Cheng, X.; Yi, R.; Gao, D.; Xiong, J. The Binding Receptors of Aβ: An Alternative Therapeutic Target for Alzheimer’s Disease. *Mol. Neurobiol.* 2016, 53, 455–471. [CrossRef] [PubMed]

13. Srivastava, A.; Das, B.; Yao, A.Y.; Yan, R. Metabotropic Glutamate Receptors in Alzheimer’s Disease Synaptic Dysfunction: Therapeutic Opportunities and Hope for the Future. *J. Alzheimer’s Dis.* 2020, 78, 1345–1361. [CrossRef] [PubMed]

14. Hu, M.; Waring, J.F.; Gopalakrishnan, M.; Li, J. Role of GSK-3 Activation and A7 NACHRs in Aβ1–42-Induced Tau Phosphorylation in PC12 Cells. *J. Neurochem.* 2008, 106, 1371–1377. [CrossRef]

15. Arora, K.; Beleaid, M.; Lantz, M.J.; Taketa, R.; Nichols, R.A. Transcriptome Profile of Nicotinic Receptor-Linked Sensitization of Beta Amyloid Neurotoxicity. *Sci. Rep.* 2020, 10, 5696. [CrossRef] [PubMed]

16. Khan, G.M.; Tong, M.; Jhun, M.; Arora, K.; Nichols, R.A. β-Amyloid Activates Presynaptic A7 Nicotinic Acetylcholine Receptors Reconstituted into a Model Nerve Cell System: Involvement of Lipid Rafts. *Eur. J. Neurosci.* 2010, 31, 788–796. [CrossRef]

17. Nordman, J.C.; Kabbani, N. An Interaction between A7 Nicotinic Receptors and a G-Protein Pathway Complex Regulates Neurite Growth in Neural Cells. *J. Cell Sci.* 2012, 125, 5502–5513. [CrossRef]

18. Magni, R.; Almofee, R.; Yusuf, S.; Mueller, C.; Vuong, N.; Almosuli, M.; Hoang, M.T.; Meade, K.; Sethi, I.; Mohammed, N.; et al. Evaluation of Pathogen Specific Urinary Peptides in Tick-Borne Illnesses. *Sci. Rep.* 2020, 10, 19340. [CrossRef]

19. Wickham, H.; Grolemund, G. *R for Data Science: Import, Tidy, Transform, Visualize, and Model Data*, 1st ed.; O’Reilly: Sebastopol, CA, USA, 2016; ISBN 978-1-4919-1039-9.

20. Forest, K.H.; Alfulaij, N.; Arora, K.; Taketa, R.; Sherrin, T.; Todorovic, C.; Lawrence, J.L.M.; Yoshikawa, G.T.; Ng, H.-L.; Hruby, V.J.; et al. Protection against β-Amyloid Neurotoxicity by a Non-Toxic Endogenous N-Terminal β-Amyloid Fragment and Its Active Hexapeptide Core Sequence. *J. Neurochem.* 2018, 144, 201–217. [CrossRef]

21. Al Shweiki, M.R.; Mönchgesang, S.; Majovsky, P.; Tu, K.; Trutschel, D.; Hoehenwarter, W. Assessment of Label-Free Quantification in Discovery Proteomics and Impact of Technological Factors and Natural Variability of Protein Abundance. *J. Proteome Res.* 2017, 16, 1410–1424. [CrossRef]

22. Abрамов, А.В.; Canevari, L.; Duchen, M.R. Beta-Amyloid Peptides Induce Mitochondrial Dysfunction and Oxidative Stress in Astrocytes and Death of Neurons through Activation of NADPH Oxidase. *J. Neurosci.* 2004, 24, 565–575. [CrossRef]

23. Kasahima, K.; Ohta, E.; Kagawa, Y.; Endo, H. Mitochondrial Functions and Estrogen Receptor-Dependent Nuclear Translocation of Pleiotrophic Specific Urinary Peptides in Tick-Borne Illnesses. *Sci. Rep.* 2020, 10, 19340. [CrossRef] [PubMed]

24. Olson, A.; Zhang, F.; Cao, H.; Baranova, A.; Slavin, M. In Silico Gene Set and Pathway Enrichment Analyses Highlight Involvement of Ion Transport in Cholinergic Pathways in Autism: Rationale for Nutritional Intervention. *Front. Neurosci.* 2021, 15, 648410. [CrossRef] [PubMed]

25. Jadiya, P.; Kolmetzky, D.W.; Tomar, D.; Di Meco, A.; Lombardi, A.A.; Lambert, J.P.; Praticò, D.; Elrod, J.W. Impaired Mitochondrial Calcium Efflux Contributes to Disease Progression in Models of Alzheimer’s Disease. *Nat. Commun.* 2019, 10, 3885. [CrossRef] [PubMed]

26. Rui, Y.; Tiwari, P.; Xie, Z.; Zheng, J.Q. Acute Impairment of Mitochondrial Trafficking by β-Amyloid Peptides in Hippocampal Neurons. *J. Neurosci.* 2006, 26, 10480–10487. [CrossRef]

27. Melo, T.Q.; van Zomeren, K.C.; Ferrari, M.F.R.; Boddeke, H.W.G.M.; Copray, J.C.V.M. Impairment of Mitochondria Dynamics by Human A53T α-Synuclein and Rescue by NAP (Davunetide) in a Cell Model for Parkinson’s Disease. *Exp. Brain Res.* 2017, 235, 731–742. [CrossRef]

28. Palmieri, F.; Scarizia, P.; Monné, M. Diseases Caused by Mutations in Mitochondrial Carrier Genes SLC25: A Review. *Biomolecules* 2020, 10, 655. [CrossRef]

29. Ito, S.; Tan, L.J.; Andoh, D.; Narita, T.; Seki, M.; Hirano, Y.; Narita, K.; Kuraoka, I.; Hiraoka, Y.; Tanaka, K. MIMX, a TFIH-Independent XPD-MMS19 Protein Complex Involved in Chromosome Segregation. *Mol. Cell* 2010, 39, 632–640. [CrossRef]

30. Jordan, V.K.; Zaveri, H.P.; Scott, D.A. 1p36 Deletion Syndrome: An Update. *Appl. Clin. Genet.* 2015, 8, 189–200. [CrossRef]

31. Albertsen, H.; Plaetke, R.; Ballard, L.; Fujimoto, E.; Connolly, J.; Lawrence, E.; Rodriguez, P.; Robertson, M.; Bradley, P.; Milner, B. Genetic Mapping of the BRCA1 Region on Chromosome 17q21. *Am. J. Hum. Genet.* 2001, 58, 478–486. [CrossRef]

32. Martin, Z.S.; Neugebauer, V.; Dineley, K.T.; Kayed, R.; Zhang, W.; Reese, L.C.; Taglialetela, G. α-Synuclein Oligomers Oppose Long-Term Potentiation and Impair Memory through a Calcineurin-Dependent Mechanism: Relevance to Human Synucleopathic Diseases: Cognitive Effects of β-Amyloid Oligomers. *J. Neurochem.* 2012, 120, 440–452. [CrossRef]

33. Qi, Y.; Ogunbunmi, E.M.; Freund, E.A.; Timerman, A.P.; Fleischer, S. FK-Binding Protein Is Associated with the Ryanodine Receptor of Skeletal Muscle in Vertebrate Animals. *J. Biol. Chem.* 1998, 273, 34813–34819. [CrossRef]

34. Schiene-Fischer, C.; Yu, C. Receptor Accessory Folding Helper Enzymes: The Functional Role of Peptidyl Prolyl Cis/Trans Isomerases. *FEBS Lett.* 2001, 495, 1–6. [CrossRef]

35. Pirttimaki, T.M.; Codadu, N.K.; Awni, A.; Pratik, P.; Nagel, D.A.; Hill, E.J.; Dineley, K.T.; Parri, H.R. A7 Nicotinic Receptor-Mediated Astrocytic Glutamatergic Transmission: The Aβ Effect in a Preclinical Alzheimer’s Mouse Model. *PLoS ONE* 2013, 8, e81828. [CrossRef]
37. DeTure, M.A.; Dickson, D.W. The Neuropathological Diagnosis of Alzheimer's Disease. *Mol. Neurodegener.* 2019, 14, 32. [CrossRef] [PubMed]
38. Nixon, R.A.; Wegiel, J.; Kumar, A.; Yu, W.H.; Peterhoff, C.; Cataldo, A.; Cuervo, A.M. Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study. *J. Neuropathol. Exp. Neurol.* 2005, 64, 113–122. [CrossRef] [PubMed]
39. John Peter, A.T.; Lachmann, J.; Rana, M.; Bunge, M.; Cabrera, M.; Unger, C. The BLOC-1 Complex Promotes Endosomal Maturation by Recruiting the Rab5 GTPase-Activating Protein Msb3. *J. Cell Biol.* 2013, 201, 97–111. [CrossRef]
40. Cullen, P.J.; Steinberg, F. To Degrade or Not to Degrade: Mechanisms and Significance of Endocytic Recycling. *Nat. Rev. Mol. Cell Biol.* 2018, 19, 679–696. [CrossRef] [PubMed]
41. Müller, M.; Ahumada-Castro, U.; Sanhueza, M.; Gonzalez-Billault, C.; Court, F.A.; Cárdenas, C. Mitochondria and Calcium Regulation as Basis of Neurodegeneration Associated with Aging. *Front. Neurosci.* 2018, 12. [CrossRef]
42. Wojtovich, A.P.; Smith, C.O.; Haynes, C.M.; Nehrke, K.W.; Brookes, P.S. Physiological Consequences of Complex II Inhibition for Aging, Disease, and the MKATP Channel. *Biochim. Biophys. Acta* 2013, 1827, 598–611. [CrossRef] [PubMed]
43. Zorova, L.D.; Popkov, V.A.; Plotnikov, E.Y.; Silachev, D.N.; Pevzner, I.B.; Jankauskas, S.S.; Babenko, V.A.; Zorov, S.D.; Balakireva, A.V.; Juhaszova, M.; et al. Mitochondrial Membrane Potential. *Anal. Biochem.* 2018, 552, 50–59. [CrossRef] [PubMed]
44. McCommis, K.S.; Finck, B.N. Mitochondrial Pyruvate Transport: A Historical Perspective and Future Research Directions. *Biochem. J.* 2015, 466, 443–454. [CrossRef] [PubMed]
45. Chevrollier, A.; Loiseau, D.; Reynier, P.; Step, G. Adenine Nucleotide Translocase 2 Is a Key Mitochondrial Protein in Cancer Metabolism. *Biochim. Biophys. Acta Bioenerg.* 2011, 1807, 562–567. [CrossRef]